Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. LVTX.NASDAQ

LAVA Therapeutics NV (LVTX NASDAQ) stock market data APIs

$2.1 0.03(1.4%) as of July 26, 2024
Price chart is built with Anychart

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LAVA Therapeutics NV Financial Data Overview

2.07
2.1
-
2.14
2.0601
1.131-4.21
55 477 K
26 292 K
12 537 K
-0.02
0.528
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'LVTX',
Type: 'Common Stock',
Name: 'LAVA Therapeutics NV',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00L04L545',
ISIN: 'NL0015000AG6',
CUSIP: NULL,
CIK: '1840748',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2021-03-25',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

LAVA Therapeutics NV Fundamental Data is available in our Financial Data APIs

  • Net Revenue 12 537 K
  • EBITDA -31 035 000
  • Earnings Per Share -1.06
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get LAVA Therapeutics NV Earnings via APIs

  • Latest Release 2024-05-21
  • EPS/Forecast -0.12

Get LAVA Therapeutics NV End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get LAVA Therapeutics NV latest news via APIs

Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?

LAVA Therapeutics NV (NASDAQ:LVTX) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK) to evaluate its anti-PD-1 therapy Keytruda (pembrolizumab) in com...

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and toler...
  • CLINICAL STUDY
  • EARNINGS RELEASES AND OPERATING RESULTS
  • LAVA THERAPEUTICS N.V
  • NASDAQ:LVTX
Do you have any questions?
support@eodhistoricaldata.com